Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816686 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
A Phase 1 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00816686: Clinical Trial Phase 1 study, sponsored by Astellas Pharma.
NCT00816686 is a Phase 1 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00816686, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.
Interventions
- BIOLOGICAL AGS-16M18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Why NCT00816686 stopped before completion
NCT00816686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which AGS-16M18 is the first listed.
NCT00816686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00816686 about?
NCT00816686 is a clinical study titled "A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer". This is a first in human study of AGS-16M18 given every week to subjects with advanced renal cell cancer. AGS-16M18 will be administered as a 60 minute IV infusion on consecutive days until the disease worsens.
What is the current status of trial NCT00816686?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00816686?
The interventions under investigation include: AGS-16M18 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00816686?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00816686's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia